Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: Updated survival analysis of JBR-10

Charles A. Butts, Keyue Ding, Lesley Seymour, Philip Twumasi-Ankrah, Barbara Graham, David Gandara, David H. Johnson, Kenneth A. Kesler, Mark Green, Mark Vincent, Yvon Cormier, Glenwood Goss, Brian Findlay, Michael Johnston, Ming Sound Tsao, Frances A. Shepherd

Research output: Contribution to journalArticle

246 Scopus citations

Abstract

Purpose: Adjuvant cisplatin-based chemotherapy (ACT) is now an accepted standard for completely resected stage II and III A non-small-cell lung cancer (NSCLC). Long-term follow-up is important to document persistent benefit and late toxicity. We report here updated overall survival (OS) and disease-specific survival (DSS) data. Patients and Methods: Patients with completely resected stage IB (T2N0, n = 219) or II (T1-2N1, n = 263) NSCLC were randomly assigned to receive 4 cycles of vinorelbine/cisplatin or observation. All efficacy analyses were performed on an intention-to-treat basis. Results: Median follow-up was 9.3 years (range, 5.8 to 13.8; 33 lost to follow-up); there were 271 deaths in 482 randomly assigned patients. ACT continues to show a benefit (hazard ratio [HR], 0.78; 95% CI, 0.61 to 0.99; P = .04). There was a trend for interaction with disease stage (P = .09; HR for stage II, 0.68; 95% CI, 0.5 to 0.92; P = .01; stage IB, HR, 1.03; 95% CI, 0.7 to 1.52; P = .87). ACT resulted in significantly prolonged DSS (HR, 0.73; 95% CI, 0.55 to 0.97; P = .03). Observation was associated with significantly higher risk of death from lung cancer (P = .02), with no difference in rates of death from other causes or second primary malignancies between the arms. Conclusion: Prolonged follow-up of patients from the JBR.10 trial continues to show a benefit in survival for adjuvant chemotherapy. This benefit appears to be confined to N1 patients. There was no increase in death from other causes in the chemotherapy arm.

Original languageEnglish (US)
Pages (from-to)29-34
Number of pages6
JournalJournal of Clinical Oncology
Volume28
Issue number1
DOIs
StatePublished - Jan 1 2010

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Butts, C. A., Ding, K., Seymour, L., Twumasi-Ankrah, P., Graham, B., Gandara, D., Johnson, D. H., Kesler, K. A., Green, M., Vincent, M., Cormier, Y., Goss, G., Findlay, B., Johnston, M., Tsao, M. S., & Shepherd, F. A. (2010). Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: Updated survival analysis of JBR-10. Journal of Clinical Oncology, 28(1), 29-34. https://doi.org/10.1200/JCO.2009.24.0333